Home Ingredients Human Milk Oligosaccharides (HMOs)
Gut HealthImmune SupportCognitive

Human Milk Oligosaccharides (HMOs)

Evidence Level
Moderate
3 Clinical Trials
5 Documented Benefits
3/5 Evidence Score

Human milk oligosaccharides (HMOs) are complex carbohydrates that are the third most abundant solid component of human breast milk, after lactose and lipids. More than 150 distinct HMO structures have been identified, with 2'-fucosyllactose (2'-FL) and lacto-N-neotetraose (LNnT) among the most studied. HMOs are not digested by the infant; instead, they reach the colon largely intact, where they selectively feed beneficial bacteria such as Bifidobacterium infantis and act as decoys that bind pathogens and protect the developing immune system. Modern supplements use bioidentical HMOs produced by microbial fermentation, allowing children and adults outside of infancy to access these compounds. The evidence base is growing rapidly, with clinical trials in infants, children, and adults examining microbiome shifts, immune outcomes, and even cognitive endpoints.

Studied Dose Adult clinical trials have used 5-20 g/day of 2'-FL and/or LNnT; infant formulas typically supply 0.2-1.5 g/L.
Active Compound Fucosylated HMOs (2'-fucosyllactose, 3-fucosyllactose), sialylated HMOs (3'-sialyllactose, 6'-sialyllactose), and core HMOs (lacto-N-neotetraose, lacto-N-tetraose).

Benefits

Supports a Healthy Gut Microbiome

HMOs are selectively fermented by beneficial Bifidobacterium species, helping shift the adult microbiome toward a composition resembling that of breastfed infants. This supports a balanced and resilient gut ecosystem.

Supported by Trial 1, Trial 3

Promotes Immune Resilience

By feeding beneficial gut bacteria and acting as soluble decoys that occupy pathogen binding sites, HMOs support the integrity of the gut barrier and the proper development and modulation of immune responses.

Supported by Trial 2, Trial 1

Supports Cognitive Development

Specific HMOs such as 2'-FL have been associated with measures of infant neurodevelopment, and growing research is exploring how the gut-brain axis modulated by HMOs may support cognition across the lifespan.

Supported by Trial 2

Helps Maintain Gut Barrier Integrity

Short-chain fatty acids produced when HMOs are fermented by gut bacteria nourish colonocytes and support tight junction proteins, helping maintain a healthy intestinal barrier.

Supported by Trial 1, Trial 2

Supports Healthy Stool Patterns

By selectively feeding beneficial microbes and increasing short-chain fatty acid production, HMOs may support comfortable, regular bowel function in adults and children.

Supported by Trial 3, Trial 1

Mechanism of action

1

Selective Bifidogenic Activity

HMOs are preferentially metabolized by Bifidobacterium infantis and other beneficial strains carrying specific glycoside hydrolases, leading to selective expansion of these populations within days of supplementation.

2

Decoy Receptor Function

Fucosylated and sialylated HMOs resemble glycans on intestinal cell surfaces, allowing them to bind and neutralize pathogens such as norovirus and certain E. coli strains before they can attach to host tissue.

3

Short-Chain Fatty Acid Production

Microbial fermentation of HMOs produces acetate, propionate, and butyrate, which lower colonic pH, nourish colonocytes, and exert systemic anti-inflammatory effects.

4

Immune Modulation

HMOs interact directly with immune cells and modulate cytokine production, influencing the balance between regulatory and inflammatory responses in the gut-associated lymphoid tissue.

Clinical trials

1
2'-FL and LNnT in Healthy Adults

Randomized, double-blind, placebo-controlled, parallel-arm trial over 2 weeks

100 healthy adults receiving 2'-FL, LNnT, or a mix versus placebo

Supplementation with HMOs at multiple doses produced a significant, selective increase in Bifidobacterium abundance and was well tolerated, supporting the use of HMOs as adult prebiotics with a microbiome-shifting effect.

2
HMOs and Infant Neurodevelopment

Prospective observational cohort study correlating breast-milk HMO content with infant cognition

Mother-infant pairs assessed at 1 month and 24 months

Concentration of 2'-fucosyllactose in breast milk at 1 month was positively associated with cognitive development scores at 24 months, supporting a role for HMOs in early brain development.

3
2'-FL and LNnT in Infant Formula

Review of multiple randomized, controlled growth and tolerance studies in formula-fed infants

Healthy infants randomized to HMO-supplemented formula or control formula

HMO-supplemented infant formulas supported normal growth and tolerance and were associated with stool microbiota and biomarker patterns closer to those of breastfed infants compared with standard formulas.

Side effects and drug interactions

Common Potential side effects

Generally well tolerated; mild gas, bloating, or loose stools may occur initially.
Symptoms typically resolve as the microbiome adapts over 1-2 weeks.
Very high intakes may cause more pronounced osmotic effects in sensitive users.
Rare reports of mild abdominal discomfort at high doses.
No major adverse events reported in clinical trials at studied doses.

Important Drug interactions

Generally considered safe; no significant drug interactions have been documented.
May modestly alter absorption of medications relying on intact gut microbiota.
Could affect timing of antibiotic recovery by reshaping the microbiome.
Consult a clinician if combining with immunosuppressive therapy.

More Gut Health Ingredients

Metabolic Health
Psyllium Husk (Plantago ovata)
Psyllium husk is the soluble fiber derived from the seed husks of Plantago ovata — the mos…
Gut Health
Pancrelipase / Pancreatin
Pancrelipase (also called pancreatin) is a standardized blend of three primary pancreatic…
Gut Health
Sunfiber® (Partially Hydrolyzed Guar Gum)
Sunfiber® is the ORIGINAL and MOST EXTENSIVELY CLINICALLY-STUDIED partially hydrolyzed gua…
Immune Support
EpiCor® (Postbiotic Yeast Fermentate — Cargill)
EpiCor® is a postbiotic ingredient from Cargill — derived from the fermentation of Sacchar…

Explore Other Ingredients

Immune Support
Probiotics (Multi-strain Blends)
Multi-strain probiotic blends are the most common form of probiotic supplements — typicall…
Cognitive
Citicoline
Citicoline (CDP-choline) is a naturally-occurring intermediate in phosphatidylcholine bios…
Cognitive
Phosphatidylserine
Phosphatidylserine (PS) is a phospholipid concentrated in neuronal cell membranes (10-20%…

Frequently asked questions about Human Milk Oligosaccharides (HMOs)

What is the recommended dosage of Human Milk Oligosaccharides (HMOs)?

The clinically studied dose for Human Milk Oligosaccharides (HMOs) is Adult clinical trials have used 5-20 g/day of 2'-FL and/or LNnT; infant formulas typically supply 0.2-1.5 g/L.. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is Human Milk Oligosaccharides (HMOs) used for?

Human Milk Oligosaccharides (HMOs) is studied for supports a healthy gut microbiome, promotes immune resilience, supports cognitive development. HMOs are selectively fermented by beneficial Bifidobacterium species, helping shift the adult microbiome toward a composition resembling that of breastfed infants. This supports a balanced and resilient gut ecosystem.

Are there side effects from taking Human Milk Oligosaccharides (HMOs)?

Reported potential side effects may include: Generally well tolerated; mild gas, bloating, or loose stools may occur initially. Symptoms typically resolve as the microbiome adapts over 1-2 weeks. Always consult a healthcare provider before starting any new supplement, especially if you have underlying conditions or take medications.

Does Human Milk Oligosaccharides (HMOs) interact with medications?

Known drug interactions may include: Generally considered safe; no significant drug interactions have been documented. May modestly alter absorption of medications relying on intact gut microbiota. Consult a pharmacist or healthcare provider if you take prescription medications.

Is Human Milk Oligosaccharides (HMOs) good for gut health?

Yes, Human Milk Oligosaccharides (HMOs) is researched for Gut Health support. HMOs are selectively fermented by beneficial Bifidobacterium species, helping shift the adult microbiome toward a composition resembling that of breastfed infants. This supports a balanced and resilient gut ecosystem.

References(4 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Elison E, Vigsnaes LK, Rindom Krogsgaard L, et al. Oral supplementation of healthy adults with 2'-O-fucosyllactose and lacto-N-neotetraose is well tolerated and shifts the intestinal microbiota. British Journal of Nutrition. 2016;Br J Nutr. 2016 Oct;116(8):1356-1368..PubMedUsed to support: RCT in 100 healthy adults showing that supplementation with 2'-FL and LNnT was well tolerated and produced a significant selective increase in Bifidobacterium abundance in stool.
  2. Berger PK, Plows JF, Jones RB, et al. Human milk oligosaccharide 2'-fucosyllactose links feedings at 1 month to cognitive development at 24 months in infants of normal and overweight mothers. PLoS One. 2020;PLoS One. 2020 Feb 11;15(2):e0228323..PubMedUsed to support: Prospective cohort showing higher 2'-fucosyllactose intake from breast milk at 1 month was associated with better cognitive development scores at 24 months.
  3. Berger PK, Bansal R, Sawardekar S, et al. Human Milk Oligosaccharides and Infant Neurodevelopment: A Narrative Review. Nutrients. 2023;Nutrients. 2023 Jan 30;15(3):719..PubMedUsed to support: Narrative review summarizing emerging evidence that specific HMOs, particularly fucosylated structures, support measurable aspects of early neurodevelopment.
  4. Vandenplas Y, Berger B, Carnielli VP, et al. Human Milk Oligosaccharides: 2'-Fucosyllactose (2'-FL) and Lacto-N-Neotetraose (LNnT) in Infant Formula. Nutrients. 2018;Nutrients. 2018 Aug 24;10(9):1161..PubMedUsed to support: Review of HMO biology and randomized infant studies indicating HMO-supplemented formulas support normal growth and produce gut microbiota and biomarker patterns closer to breastfed infants.